SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,961,002 | +24.5% | 65,674 | +17.6% | 0.05% | +39.4% |
| Q2 2023 | $6,396,515 | +247.0% | 55,855 | +317.6% | 0.03% | +230.0% |
| Q1 2023 | $1,843,338 | +89.1% | 13,374 | +77.8% | 0.01% | +100.0% |
| Q4 2022 | $974,701 | -46.2% | 7,522 | -29.3% | 0.01% | 0.0% |
| Q4 2020 | $1,813,000 | -96.9% | 10,636 | -97.4% | 0.01% | -97.1% |
| Q3 2020 | $58,436,000 | -41.2% | 416,124 | -32.8% | 0.17% | -48.0% |
| Q2 2020 | $99,325,000 | -32.7% | 619,467 | -58.9% | 0.33% | +0.9% |
| Q1 2020 | $147,480,000 | +32.3% | 1,507,672 | +74.5% | 0.32% | -21.0% |
| Q4 2019 | $111,506,000 | +55.3% | 864,123 | -9.4% | 0.41% | +45.4% |
| Q3 2019 | $71,805,000 | -55.8% | 953,332 | -10.8% | 0.28% | -54.8% |
| Q2 2019 | $162,407,000 | +25.8% | 1,068,816 | -1.3% | 0.62% | +21.4% |
| Q1 2019 | $129,089,000 | -29.8% | 1,083,053 | -35.7% | 0.51% | -39.3% |
| Q4 2018 | $183,954,000 | -27.8% | 1,685,638 | +6.8% | 0.85% | -11.5% |
| Q3 2018 | $254,921,000 | +23.8% | 1,578,360 | +1.3% | 0.96% | +10.6% |
| Q2 2018 | $205,947,000 | +69.5% | 1,558,077 | -5.0% | 0.86% | +53.1% |
| Q1 2018 | $121,498,000 | +38.1% | 1,639,865 | +3.7% | 0.56% | +42.3% |
| Q4 2017 | $87,996,000 | +35.5% | 1,581,525 | +10.5% | 0.40% | +30.6% |
| Q3 2017 | $64,947,000 | +1111.7% | 1,431,813 | +800.5% | 0.30% | +1069.2% |
| Q2 2017 | $5,360,000 | +46.2% | 159,008 | +28.4% | 0.03% | +44.4% |
| Q1 2017 | $3,666,000 | +6.7% | 123,840 | -1.2% | 0.02% | -5.3% |
| Q4 2016 | $3,437,000 | -48.5% | 125,302 | +15.3% | 0.02% | -44.1% |
| Q3 2016 | $6,676,000 | +400.1% | 108,712 | +55.3% | 0.03% | +385.7% |
| Q2 2016 | $1,335,000 | +22.1% | 70,000 | +25.0% | 0.01% | +16.7% |
| Q1 2016 | $1,093,000 | -49.4% | 56,000 | 0.0% | 0.01% | -45.5% |
| Q4 2015 | $2,160,000 | +4.4% | 56,000 | -13.0% | 0.01% | 0.0% |
| Q3 2015 | $2,068,000 | +5.2% | 64,400 | -0.3% | 0.01% | +22.2% |
| Q2 2015 | $1,966,000 | – | 64,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |